Semaglutide in the United States
FDA-approved as Wegovy (chronic weight management), Ozempic (T2D), and Rybelsus (oral T2D). Compounded semaglutide entered legal grey zone after the May 2025 FDA shortage-list resolution; 503A pharmacies still legally produce custom-dose preparations under personalisation rules. Branded prices stayed stubbornly high; compounded is cheaper but the trust profile depends entirely on the source.
FDA-approved Wegovy (obesity), Ozempic (T2D), Rybelsus (oral T2D). Prescription-only. Post-May-2025 FDA shortage resolution, mass-compounding ended; 503A pharmacies retain personalisation-rule pathway.
What it actually costs.
Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.
Per month, Novo Nordisk list. Insurance dependent — Wegovy weight-management coverage expanding 2025-26.
Per month. Post-shortage, compounding only legal under personalisation rules — different dose / additive than the brand.
Henry Meds, Hims, Mochi, LifeMD. Includes consult + shipping.
Per month, Novo Nordisk list. Insurance dependent. Lower bioavailability than injectable.
How to get it — on the right side of the line.
Branded through insurance or cash
Wegovy weight-management coverage is expanding under 2025-26 employer plans. Cash retail near list. Ozempic + Rybelsus typically T2D-only for insurance.
Compounded via a telehealth service
Henry Meds, Hims, Mochi, LifeMD, Ro. Post-shortage personalisation rules require a different dose / additive than the brand. The Panya rubric scores each on cold-chain, COA, response time. Expect $249-$399 monthly all-in.
What channels actually work here.
Standard retail pharmacy. Wegovy supply mostly recovered post-2024 shortage.
503A pharmacies under personalisation rules. State variance.
Grey-market — not recommended by Panya.
Major channel. Low-friction onboarding.
Post-May-2025, mass-compounded semaglutide is no longer legal — only personalised compounding (e.g., with B12 additive or non-standard dose) qualifies. Some compounding pharmacies + telehealth platforms exited the segment; the survivors typically use a compliant personalisation pathway. Verify your prescription is for a personalised formulation, not just bulk semaglutide.
Tirzepatide in the US
Mounjaro / Zepbound — dual GLP-1 + GIP agonist. Eli Lilly. Stronger weight effect head-to-head than semaglutide; also more expensive and supply has been more constrained globally.
Match me to a vendor in the US.
Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.